• AAPL 169.02
  • TSLA 162.13
  • AMZN 176.59
  • MSFT 409.06
  • INTC 34.5
  • EURUSD 1.0728
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. BR /
  3. ARGX.BR

Argen-X (ARGX BR) stock market data APIs

€351 1.1(0.3%) as of April 24, 2024

Argen-X Financial Data Overview

349.9
351
-
356.4
348.5
271-494.1
20 795 M
59 431 K
1 269 M
-1.58
0.355
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ARGX',
Type: 'Common Stock',
Name: 'Argen-X',
Exchange: 'BR',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Belgium',
CountryISO: 'BE',
ISIN: 'NL0010832176',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: '2017-05-18',
InternationalDomestic: 'International/Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Argen-X Fundamental Data is available in our Financial Data APIs

  • Net Revenue 1 269 M
  • EBITDA -316 815 008
  • Earnings Per Share -4.85
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Argen-X Earnings via APIs

  • Latest Release 2024-03-12
  • EPS/Forecast -1.5

Get Argen-X End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Argen-X latest news via APIs

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

argenx SE ADHERE data show VYVGART®Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over...

Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday

Shares of Argenx ARGX rose 11.2% on Mar 21, after Japan-based Chugai Pharmaceutical posted disappointing results from a late-stage study evaluating Enspryng (satralizumab) as a potential treatment for...
Do you have any questions?
support@eodhistoricaldata.com